Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.